dactolisib (RTB101) - Novartis, PureTech
fenretinide (RT-101) - ReVision Therapeutics
sirolimus - generics
blisibimod (A-623) - Anthera
http://www.globenewswire.com/news-release/2019/05/13/1822420/0/en/resTORbio-to-Present-RTB101-Phase-2b-Clinical-Trial-Data-at-American-Thoracic-Society-2019-International-Conference.html
 
May 13, 2019
 
Prev Next